Rational development of a vaccine against tick-borne rickettsioses
蜱传立克次体病疫苗的合理研制
基本信息
- 批准号:10522492
- 负责人:
- 金额:$ 81.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAnimalsAntibodiesArthropodsAttenuatedAttenuated VaccinesBacteriaBacteriophagesBrazilBypassCD8-Positive T-LymphocytesCD8B1 geneCase Fatality RatesCellsCellular ImmunityCenters for Disease Control and Prevention (U.S.)DevelopmentDiagnostic ProcedureDiseaseDoseElementsEnsureEvaluationExperimental ModelsGenesGenetic EngineeringGoalsGram-Negative BacteriaHandHealthHumanHumoral ImmunitiesImmuneImmune signalingImmunityImmunizationImmunizeImmunoglobulin GImmunologicsIn VitroIncidenceInfectionIntegraseInterferon Type IIInterferonsIntravenousLeftLesionLifeMemoryModelingNeedlesPathogenicityPathologicPhenotypePilot ProjectsPolyvalent VaccinePreventionProteinsPublic HealthPublishingReportingResearchResourcesRickettsiaRickettsia InfectionsRickettsia parkeriRifampicin resistanceRocky Mountain Spotted FeverRoleSafetySignal TransductionT memory cellTLR4 geneTestingTicksTimeUnited StatesVaccinationVaccine DesignVaccinesVirulenceVirulentanti-tick vaccinecross immunityefficacy evaluationimmunogenicityimmunoprophylaxisinnovationinsightmouse modelmutantneutralizing antibodynovelnovel strategiesnovel vaccinespathogenpreventprotective efficacyrational designspotted fevertick bitetick transmissiontick-bornetransmission processvaccine accessvaccine candidatevaccine developmentvaccine efficacyvaccine trialvaccine-induced immunity
项目摘要
Abstract
Rickettsiae are a group of arthropod-associated, obligately intracellular Gram-negative bacteria that are closely
related but potentially cause life-threatening infection in humans. Tick-borne rickettsioses (TBRs) are
increasingly posing serious threat to the public health in the US due to increased incidence and lack of
commercially available vaccine for prevention. Therefore, a safe and effective vaccine against TBRs will be
an important resource that will ensure the Nation’s capability to prevent this group of diseases. Our long-
term goal is to develop novel approaches for safe and effective immunoprophylaxis of TBRs. Our recently
published and pilot studies demonstrated that live-attenuated R. parkeri mutant 3A2 conferred full protection
against lethal challenge of two highly virulent rickettsiae in mouse models, accompanied by generating high titers
of IgG antibodies reactive against several pathogenic rickettsial species and significantly elevated type 1 T cell
memory immunity. These findings support the proof-of-concept that live-attenuated vaccine candidate serves a
feasible and effective approach to prevent TBRs and study vaccine-induced memory immunity against TBRs.
Thus, the objectives of this R01 application are to generate a safe and efficacious live-attenuated vaccine
(LAV) against TBRs, define the protective efficacy of LAV against homologous and heterologous rickettsial
strains, and mechanistically determine the immune correlates of vaccine-elicited protection against tick
transmission of TBRs. To achieve these objectives, we propose three specific aims to test the central
hypothesis that the LAV will elicit high quality CD8+ T memory cells and rickettsiae-specific neutralizing
antibodies to confer complete protection against natural acquisition of TBRs as a safe and efficacious polyvalent
vaccine candidate. Aim 1 will optimize R. parkeri mutants genetically to reduce virulence, enhance safety while
maintaining immunogenicity. Aim 2 will define the efficacy of genetically optimized R. parkeri mutants in
protecting against TBRs in both needle-challenge and tick transmission animal models. Aim 3 will identify the
immunological correlates of vaccine-induced protection against TBRs. Upon the completion of the proposed
research, we expect to define the first multivalent vaccine candidate for TBR and reveal the novel elements of
host immunity responsible for prevention from natural transmission of TBRs. This will have significant positive
effects on human health because it will provide the basic information required to ultimately develop a safe,
effective, and tractable vaccine against TBRs.
摘要
立克次体是一组与节肢动物相关的细胞内专性革兰氏阴性细菌,它们与
相关但可能会在人类中引起危及生命的感染。壁虱传播立克次体病(TBR)是
由于发病率的增加和缺乏,对美国的公共健康构成日益严重的威胁
市面上有预防用疫苗。因此,一种安全有效的TBRs疫苗将是
这是一个重要的资源,将确保国家预防这类疾病的能力。我们的长-
长期目标是开发安全有效的TBRs免疫预防的新方法。我们最近
已发表的和初步研究表明,减毒帕氏杆菌突变株3A2具有完全保护作用。
在小鼠模型中对抗两种高毒力立克次体的致死性攻击,并产生高滴度
对几种致病立克次体有反应的抗体和显著升高的1型T细胞
记忆免疫力。这些发现支持概念验证,即减毒活疫苗候选者
预防TBRs的可行有效途径和研究疫苗诱导的TBRs记忆免疫。
因此,R01应用的目标是产生一种安全有效的减毒活疫苗
(LAV)抗结核分枝杆菌,定义LAV对同源和异种立克次体的保护效力
菌株,并从机械上确定疫苗诱导的抗蚤保护的免疫相关性
Tbr的传播。为了实现这些目标,我们提出了三个具体目标来测试中央
假设LAV将诱导高质量的CD8+T记忆细胞和立克次体特异性中和
抗体作为一种安全有效的多价抗体,可完全预防自然获得的TBR
候选疫苗。目标1将对帕氏杆菌突变体进行遗传优化,以降低毒力,增强安全性,同时
保持免疫原性。目标2将确定遗传优化的帕克氏杆菌突变体在
在针刺法和壁虱传播法动物模型中预防TBR。目标3将确定
疫苗诱导的TBRs保护作用的免疫学相关性。在完成建议的
研究,我们希望定义第一个用于TBR的多价候选疫苗,并揭示新的元素
宿主免疫负责预防TBR的自然传播。这将产生重大的积极影响
对人类健康的影响,因为它将提供最终开发安全、
有效的、易处理的TBRS疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rong Megan Fang其他文献
Rong Megan Fang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rong Megan Fang', 18)}}的其他基金
Rational development of a vaccine against tick-borne rickettsioses
蜱传立克次体病疫苗的合理研制
- 批准号:
10673846 - 财政年份:2022
- 资助金额:
$ 81.8万 - 项目类别:
Mechanisms by which rickettsiae subvert autophagy pathway in macrophages
立克次体破坏巨噬细胞自噬途径的机制
- 批准号:
10461972 - 财政年份:2021
- 资助金额:
$ 81.8万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 81.8万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 81.8万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 81.8万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 81.8万 - 项目类别:
Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
- 批准号:
23KK0126 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 81.8万 - 项目类别:
Training Grant